c-Src表达在转移性乳腺癌中的预后价值  

Prognostic Value of c-Src Expression in Metastatic Breast Cancer

作　　者：张凌云[1] 滕月娥[1] 曲秀娟[1] 刘云鹏[1] 侯科佐[1] 

机构地区：[1]中国医科大学附属第一医院肿瘤内科,沈阳市110001

出　　处：《中国肿瘤临床》2012年第5期245-248,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金(编号:30700807);辽宁省高等学校科研项目计划(编号:2008S246);辽宁省科学技术计划项目(编号:2010225032)资助~~

摘　　要：目的:实验研究表明非受体酪氨酸激酶(c-Src)与乳腺癌的转移密切相关,本研究探讨c-Src表达在转移性乳腺癌中的预后价值。方法:收集2007年1月至2010年10月102例转移性乳腺癌患者的原发癌组织蜡块,免疫组化法检测c-Src的表达。回顾性分析c-Src表达与乳腺癌临床病理特征的关系、生存分析及Cox风险模型,探讨c-Src表达对患者预后的影响。结果:102例乳腺癌组织中c-Src表达率为54.9%,c-Src高表达于无进展生存期(PFS)≤3年(P=0.048)的患者。生存分析显示c-Src阳性较阴性的患者疾病特异性生存(DSS)显著缩短(P=0.017)。分层分析显示激素受体(HR)阳性/c-Src阳性患者DSS最短,而HR阳性/c-Src阴性的患者DSS最长(P=0.016)。多因素分析显示,HR阳性/c-Src阳性、PFS≤3年、肿瘤组织学分级Ⅲ级和年龄≤35岁均是较差的DSS独立预测因子。结论:转移性乳腺癌患者中,HR阳性且c-Src阳性预测患者的不良预后。Objective： c-Src is reported to be critical for breast cancer progression. However, few reports have been published on the prognostic value ofc-Src in breast cancer. The present study aims to explore c-Src expression and to evaluate its effects on the prog- nosis of metastatic breast cancer （ MBC ）. Methods： Paraffin-embedded primary tumor tissue sections from 102 MBC patients were collected consecutively from January 2007 to October 2010. Immunohistochemical staining was conducted to determine c-Src expres- sion. Clinical data during the follow up after 7 to 143 （ median, 40 ） months after final diagnosis were analyzed in retrospect. Survival analysis and the Cox proportional hazards model were used to explore the prognostic value of c-Src expression in breast cancer. Resuits： The c-Src expression rate in 102 MBC patients was 54.9%. The c-Src expression rate was significantly higher among breast can- cer patients with a progression-free survival （ PFS ） of less than 3 years （ P = 0.048 ）. The survival analysis clearly indicated that patients with positive c-Src expression had poor disease-specific survival （ DSS ） compared with those with negative expression （ P = 0.017 ）. The stratified analysis demonstrated that c-Src expression showed a significantly poor DSS （ P = 0.016 ） in estrogen receptor/ progesterone receptor -positive patients. No significant differences in DSS were observed （ P = 0.904 ） among HR-negative patients. The multivariate analysis indicates that HR＋/c-Src＋ expression and the histologic grading of tumors and age below 35 years are the independent predictors of DSS for MBC patients. Conclusion： A positive hormone receptor plus HR＋/c-Src＋ expression predicts a poor prognosis in MBC patients.

关 键 词：c—Src 转移性乳腺癌 ER/PR预后 

分 类 号：R737.9[医药卫生—肿瘤]